Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Sauerland

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
Blood|July 16, 2005
Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemiaMatthias Stelljes, Martin Bornhauser, Matthias Kroger, et al.
Blood|June 11, 1999
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative GroupT Büchner, W Hiddemann, B Wörmann, et al.
Leukemia & Lymphoma|October 1, 1996
Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOGT Haferlach, J M Bennett, H Löffler, et al.
The British Journal of Dermatology|April 17, 2010
Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosusA Kuhn, A M Meuth, D Bein, et al.
Cancer|October 22, 2022
Molecular profiling of patients with cytogenetically normal acute myeloid leukemia and hyperleukocytosisFriederike Pastore, Alessandro Pastore, Maja Rothenberg-Thurley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2011
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patientsU Brunnberg, M Mohr, R Noppeney, et al.
Leukemia|December 19, 2017
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemiaM Rothenberg-Thurley, S Amler, D Goerlich, et al.
Leukemia|October 24, 2013
Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCGM Fiegl, M Unterhalt, W Kern, et al.
Leukemia|February 24, 2018
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemiaMaja Rothenberg-Thurley, Susanne Amler, Dennis Goerlich, et al.
Leukemia|June 11, 2014
Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapseT Köhnke, D Sauter, K Ringel, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Blood|July 16, 2005
Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemiaMatthias Stelljes, Martin Bornhauser, Matthias Kroger, et al.
Blood|June 11, 1999
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative GroupT Büchner, W Hiddemann, B Wörmann, et al.
Leukemia & Lymphoma|October 1, 1996
Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOGT Haferlach, J M Bennett, H Löffler, et al.
The British Journal of Dermatology|April 17, 2010
Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosusA Kuhn, A M Meuth, D Bein, et al.
Cancer|October 22, 2022
Molecular profiling of patients with cytogenetically normal acute myeloid leukemia and hyperleukocytosisFriederike Pastore, Alessandro Pastore, Maja Rothenberg-Thurley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2011
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patientsU Brunnberg, M Mohr, R Noppeney, et al.
Leukemia|December 19, 2017
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemiaM Rothenberg-Thurley, S Amler, D Goerlich, et al.
Leukemia|October 24, 2013
Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCGM Fiegl, M Unterhalt, W Kern, et al.
Leukemia|February 24, 2018
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemiaMaja Rothenberg-Thurley, Susanne Amler, Dennis Goerlich, et al.
Leukemia|June 11, 2014
Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapseT Köhnke, D Sauter, K Ringel, et al.
Pageof 7